Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. Haematologica 2023 Jan 01;108(1):250-256
Date
09/16/2022Pubmed ID
36106394Pubmed Central ID
PMC9827178DOI
10.3324/haematol.2022.281309Scopus ID
2-s2.0-85145424654 (requires institutional sign-in at Scopus site) 4 CitationsAuthor List
Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WRAuthors
Sameem Abedin MD Associate Professor in the Medicine department at Medical College of WisconsinWilliam R. Drobyski MD Professor in the Medicine department at Medical College of Wisconsin
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
Lyndsey Runaas MD Assistant Professor in the Medicine department at Medical College of Wisconsin
Nirav N. Shah MD Associate Professor in the Medicine department at Medical College of Wisconsin
Aniko Szabo PhD Professor in the Data Science Institute department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Antibodies, Monoclonal, HumanizedGastrointestinal Tract
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
